[Skip to Content]
[Skip to Content Landing]
February 6, 1954


Author Affiliations


From the Department of Dermatology and Syphilology of Indianapolis General Hospital, the Alembert Winthrop Brayton Skin and Cancer Foundation, and its allied P. C. Reilly Laboratory of Mycology.; Much of the information on the newer antituberculous agents was obtained from the notes of Drs. J. W. Smith and J. G. Evans of the Lilly Research Division of Indianapolis General Hospital on the Veterans Administration, Army, and Navy Conference on Chemotherapy in Tuberculosis held at Atlanta, Ga., on Feb. 9 to 12, 1953.

JAMA. 1954;154(6):475-481. doi:10.1001/jama.1954.02940400013004

The rather unsatisfactory results of previous therapies in cutaneous tuberculosis led us to investigate the newer agents introduced for the treatment of this disease in other organs. Because tuberculoderms are uncommon, it is difficult to assemble individually any large series of such cases for an evaluation of their curative plans. Thus, for our guidance, we turned to the larger therapeutic studies done on the more prevalent pulmonary forms of this malady, and we selected isoniazid for trial. Since sarcoidosis presents clinical and histopathological findings similar to tuberculosis and since it is also difficult to handle, we included two cases of this somewhat rare entity in this study.

NEWER ANTITUBERCULOUS AGENTS  The recent Veterans Administration, Army, and Navy Conference on Chemotherapy in Tuberculosis1 contributed much to our better understanding of the newer antituberculous agents. This group seems agreed that amithiozone (Tibione)1a is too toxic to warrant further employment. This

First Page Preview View Large
First page PDF preview
First page PDF preview